Somnomed Limited (AU:SOM) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
SomnoMed Limited reported a promising FY24 with a revenue increase of 9.6% to $91.7 million and a product gross margin of 69%, though EBITDA dropped to $0.6 million from the previous year’s $2.1 million. The company announced an expected FY25 revenue of around $100 million with EBITDA surpassing $5 million, after a strong start with revenues up 20% in the first 8 weeks. Additionally, SomnoMed is preparing to respond to the US FDA’s queries, potentially leading to a global beta market entry in 2025.
For further insights into AU:SOM stock, check out TipRanks’ Stock Analysis page.